Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trabectedin study in advanced rearranged mesenchymal chondrosarcoma
2019-003733-41Phase 2Active
- Sponsor
- Italian Sarcoma Group
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in mesenchymal chondrosarcoma (MCS), sponsored by Italian Sarcoma Group. Primary endpoints: Choi response rate and Response rate according to RECIST version 1.1. Started Jun 2021; status: active.
02
Drugs
trabectedin
03
Conditions
mesenchymal chondrosarcoma (MCS)
Beyond the preview
Go deeper on 2019-003733-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003733-41.